Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 5:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2641–2664 of 4,226 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Injectable Placebo Clear all

Conditions: Type 1 Diabetes
Interventions: CT-868, Placebo, Victoza; Drug
Lead sponsor: Carmot Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Infections, Bacterial
Interventions: GSK1322322 Initial fit for purpose tablets, GSK1322322 over granulated tablets, GSK1322322 intended commercial tablets, Placebo tablets, 13C-GSK1322322 stable isotope powder, GSK1322322 for injection, Placebo injection; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Chronic Pain Due to Injury
Interventions: Oxytocin, Placebo; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 66 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Obesity & Overweight, Mobility Disability, HOMA-IR
Interventions: Enobosarm, Semaglutide (Wegovy) weekly injection; Drug
Lead sponsor: Veru Inc.; Industry
Eligibility: 65 Years to 100 Years
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 13
States / cities: Phoenix, Arizona • Doral, Florida • Miami, Florida + 7 more

Conditions: Osteoarthritis, Knee
Interventions: Placebo, Lorecivivint; Drug
Lead sponsor: Biosplice Therapeutics, Inc.; Industry
Eligibility: 41 Years to 81 Years
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 42
States / cities: Tucson, Arizona • Anaheim, California • Pomona, California + 39 more

Conditions: Hypercholesterolemia, Mixed Dyslipidemia, Type 2 Diabetes
Interventions: Evolocumab, Placebo to Evolocumab; Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 424 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 46
States / cities: Tuscumbia, Alabama • Phoenix, Arizona • Lomita, California + 39 more

Conditions: Systemic Sclerosis
Interventions: Belimumab, Rituximab, Placebo Subcutaneous Injection, Placebo Infusion, MMF; Drug · Other
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Myocardial Ischemia, Congestive Heart Failure, Cardiovascular Disease
Interventions: Autologous Stem Cells; Biological
Lead sponsor: Losordo, Douglas, M.D.; Individual
Eligibility: 21 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Keratoconjunctivitis Due to Adenovirus, Viral Shedding
Interventions: Zirgan, genteal gel; Drug
Lead sponsor: Lifelong Vision Foundation; Other
Eligibility: 14 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Chesterfield, Missouri

Conditions: Breast Cancer, Pain, Postoperative, BRCA1 Mutation, BRCA2 Mutation, Breast Diseases, Neoplasms
Interventions: Botulinum Toxin Type A, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 131 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Low Testosterone
Interventions: TAK-448, TAK-448 Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 60 Years and older · Male only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Delayed Graft Function
Interventions: QPI-1002, Placebo; Drug · Other
Lead sponsor: Quark Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 594 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more

Conditions: Osteoarthritis of the Knee
Interventions: Gel-200, Placebo; Device
Lead sponsor: Seikagaku Corporation; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 379 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Plantation, Florida

Conditions: Healthy
Interventions: Ciraparantag, Placebo, Rivaroxaban; Drug
Lead sponsor: Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.; Industry
Eligibility: 50 Years to 75 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: Hip Arthropathy, Postoperative Pain, Acute, Pain, Postoperative
Interventions: Active bupivacaine 0.375% PENG block, Placebo normal saline PENG block; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: San Diego, California

Conditions: Psoriatic Arthritis
Interventions: Abatacept, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 19
States / cities: Huntsville, Alabama • Palm Desert, California • Palo Alto, California + 16 more

Conditions: Post Operative Pain, Impacted Third Molar Tooth, Muscle Pain
Interventions: Temporo-masseteric Nerve Block Injection, Oral Pain Medications only; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Major Depressive Disorder
Interventions: Tocilizumab, Placebo, Whole-Body Hyperthermia; Drug · Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Ischemic Stroke, Malignant Edema
Interventions: Glyburide for Injection, Placebo; Drug
Lead sponsor: Remedy Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 17
States / cities: Tucson, Arizona • Stanford, California • New Haven, Connecticut + 14 more

Conditions: Thyroid Eye Disease, TED
Interventions: MHB018A, MHB018A placebo; Drug
Lead sponsor: Minghui Pharmaceutical (Hangzhou) Ltd; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Coral Gables, Florida

Conditions: Overweight and Obesity, Type2 Diabetes, NAFLD
Interventions: DD01, Placebo; Drug
Lead sponsor: Neuraly, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 3
States / cities: Chula Vista, California • Fort Myers, Florida • Orlando, Florida

Conditions: Moderate to Severe Plaque Psoriasis
Interventions: 210 mg brodalumab, 140 mg brodalumab, ustekinumab, placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,831 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 67
States / cities: Birmingham, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 56 more

Conditions: Episodic Migraine
Interventions: Galcanezumab, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 533 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 38
States / cities: Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 33 more

Conditions: Scar Prevention
Interventions: EXC 001, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 5
States / cities: La Jolla, California • Chicago, Illinois • St Louis, Missouri + 2 more

Search by objective public record fields.

A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes

A Three-part Study to Determine the Safety, Tolerability and Pharmacokinetics of GSK1322322 in Healthy Volunteers and Healthy Male Japanese Subjects

Effects of Intramuscular (IM) Oxytocin on Pupil Diameter and Heart Rate Variability (HRV)

Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss

A Long-Term Safety and Efficacy Study of Lorecivivint in Subjects With Osteoarthritis of the Knee

Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia

Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis

Stem Cell Study for Patients With Heart Failure

A Placebo Controlled Comparison of Topical Zirgan Versus Genteal Gel for the Treatment of Adenovirus Conjunctivitis

Botulinum Toxin A (Botox) in Tissue Expander Breast Reconstruction

Effects of TAK-448 in Middle-aged and Older Men With Low Testosterone

QPI-1002 for Prevention of Delayed Graft Function in Recipients of an Older Donor Kidney Transplant

Gel-200 Versus Placebo in Osteoarthritis of the Knee

Phase 2 Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT

Pericapsular Nerve Group Block (PENG) for Hip Surgery

Safety and Efficacy of Abatacept Versus Placebo in Participants With Psoriatic Arthritis

Jaw Muscle Pain Post Wisdom Molar Surgery

Mild-Intensity Whole Body Hyperthermia (WBH) for Major Depressive Disorder

Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals

Treatment of Active Thyroid Eye Disease With MHB018A in a Randomized, Placebo-Controlled Study

A Phase 1 Study of DD01 in Overweight/Obese Subjects With T2DM and NAFLD

P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis

A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine

Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars From Prior Breast Surgery